Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will pain patch blunt demand for needles?

This article was originally published in The Gray Sheet

Executive Summary

Alza's E-Trans fentanyl, needle-free, patient-controlled pain management patch receives 48-hour satisfaction rating of 80%, identical to that of patient-controlled morphine IV, according to 636-patient, 33-site study in March 17 issue of the Journal of the American Medical Association. The J&J subsidiary filed a new drug application with FDA in September and anticipates "some consultation" with CDRH prior to approval...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel